Increased expression of TGF- beta 1 reduces tumor growth of human U-87 Glioblastoma Cells in vivo

The role that transforming growth factor beta 1 (TGF- beta 1) plays in influencing growth of glioma cells is somewhat controversial. To further understand the potential growth-regulatory effects of TGF- beta 1,we constructed an animal astroglial tumor model by injecting either wild-type or virally t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Immunology, Immunotherapy Immunotherapy, 2006-08, Vol.55 (8), p.918-927
Hauptverfasser: Pan, J-J, Chang, W-J, Barone, T A, Plunkett, R J, Ostrow, P T, Greenberg, S J
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The role that transforming growth factor beta 1 (TGF- beta 1) plays in influencing growth of glioma cells is somewhat controversial. To further understand the potential growth-regulatory effects of TGF- beta 1,we constructed an animal astroglial tumor model by injecting either wild-type or virally transduced human U-87 glioblastoma cells into nude rat brains. Wild type U-87 cells produced very low amounts of TGF- beta 1 and were highly tumorigenic. In contrast, U-87 cells transduced to express high levels of TGF- beta 1 showed reduced tumor size in vivo, in a dose-dependent manner. This reduction in tumor size was not due to either decreased vascularity or increased apoptosis. To test whether TGF- beta 1 overproduction inhibited tumor growth through an autocrine mechanism, the highest TGF- beta 1 producing cells were then double transduced with a vector expressing the kinase-truncated type II TGF- beta receptor. Cells expressing high levels of truncated TGF- beta receptor were less sensitive to TGF- beta 1 mediated growth inhibition in vitro and produced more aggressive tumors in vivo. The data suggest that the degree of tumorigenicity of the U-87 high-grade glioblastoma cell line may be associated with correspondingly low level of production of TGF- beta 1. These results also would tend to support the possibility that TGF- beta 1 may be useful in treating some high-grade gliomas.
ISSN:0340-7004
1365-2567
DOI:10.1007/s00262-005-0083-9